

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 13D0521001	(X3) Date Survey Completed 10/15/2024
Name of Provider or Supplier Madison Memorial Hospital Lab	Street Address, City, State 450 E Main St, Rexburg, ID	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a review of the Centers for Medicare and Medicaid (CMS) proficiency testing (PT) data report (Report 155D), graded results from the College of American Pathologists (CAP) and an interview with the laboratory manager on 10/08/24, the laboratory failed to successfully participate and achieve an overall satisfactory score for two (2) of three (3) testing events in 2024 for the specialty of toxicology. See D2111, and D2118</p>
D2111	<p>TOXICOLOGY CFR(s): 493.845(c)</p>

Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events.

This STANDARD is not met as evidenced by:
Based on a review of the Centers for Medicare and Medicaid (CMS) Proficiency Testing (PT) data report (Report 155D), graded PT results from the College of American Pathologists (CAP) and an interview with the laboratory manager on 10/08/24, the laboratory failed to participate in two (2) consecutive PT events for the analytes phenobarbitol and phenytoin for the year 2024. The findings include: 1. A review of Report 155D and graded PT results from API identified that the laboratory failed to participate and hence failed to achieve satisfactory performance for events one (1) and two (2) in 2024 for the specialty of toxicology for the analytes phenobarbitol and phenytoin. Analyte Year Event Score Phenobarbitol 2024 1 0% Phenobarbitol 2024 2 0% Phenytoin 2024 1 0% Phenytoin 2024 2 0% 2. An interview with the laboratory manager on 10/08/2024 at 10:47 AM confirmed the above findings.

D2118

TOXICOLOGY
CFR(s): 493.845(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:
Based on a review of the Centers for Medicare and Medicaid (CMS) Proficiency Testing (PT) data report (Report 155D), graded PT results from the College of American Pathologists (CAP) and an interview with the laboratory manager on 10/08/24, the laboratory failed to achieve satisfactory performance for two (2) consecutive PT events for the analytes phenobarbitol and phenytoin. The findings include: 1. A review of Report 155D and graded PT results from API identified that the laboratory failed to achieve satisfactory performance for events one (1) in 2024 and two (2) in 2024 for the specialty of toxicology for the analyte phenytoin. Analyte Year Event Score Phenobarbitol 2024 1 0% Phenobarbitol 2024 2 0% Phenytoin 2024 1 0% Phenytoin 2024 2 0% 2. An interview with the laboratory manager on 10/08/2024 at 10:47 AM confirmed the above findings.